Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PFE and the rest of the Medical group's stocks.
Pfizer is one of 816 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PFE is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for PFE's full-year earnings has moved 0.39% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, PFE has gained about 18.89% so far this year. At the same time, Medical stocks have gained an average of 0.71%. This means that Pfizer is performing better than its sector in terms of year-to-date returns.
To break things down more, PFE belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 6.91% so far this year, meaning that PFE is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on PFE as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Pfizer (PFE - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of PFE and the rest of the Medical group's stocks.
Pfizer is one of 816 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PFE is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for PFE's full-year earnings has moved 0.39% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, PFE has gained about 18.89% so far this year. At the same time, Medical stocks have gained an average of 0.71%. This means that Pfizer is performing better than its sector in terms of year-to-date returns.
To break things down more, PFE belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual companies and currently sits at #32 in the Zacks Industry Rank. On average, this group has gained an average of 6.91% so far this year, meaning that PFE is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on PFE as it attempts to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PFE - FREE